Overview of EGFR-Mutant Advanced NSCLC
Panelists discuss how advanced EGFR-mutant non-small cell lung cancer (NSCLC) requires careful molecular testing and staging for optimal targeted therapy selection, with particular attention to patient demographics and presentation patterns.
Now Viewing
EP: 1.Overview of EGFR-Mutant Advanced NSCLC
EP: 2.EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians
EP: 3.Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach
EP: 4.Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective
EP: 5.Tailoring Patient Education and Resources in EGFR-Mutant Advanced NSCLC
EP: 6.Navigating EGFR-Mutant Advanced NSCLC Cancer Treatment: A Patient's Journey
EP: 7.Shared Decision Making in EGFR-Mutant Advanced NSCLC
EP: 8.Preparing Patients for Treatment: Education, Administration, and Side Effect Management with Amivantamab in EGFR-Mutant NSCLC
EP: 9.Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
EP: 10.Patient Perspectives on Managing Side Effects from Amivantamab
EP: 11.Comprehensive Supportive Care for EGFR-Mutant Advanced NSCLC
EP: 12.Patient Perspective: Key Aspects of Supportive Care in the EGFR-Mutant Advanced NSCLC Journey
EP: 13.Future Perspectives in EGFR-Mutant Advanced NSCLC
Video content above is prompted by the following:
- Please provide a brief overview of advanced EGFR-mutant NSCLC
- How might a typical patient present with advanced EGFR-mutant NSCLC?
- What are the key risk factors? (age, gender, family history, other demographics)
- What steps do you take to diagnose, risk assess, and stage your patients with advanced EGFR-mutant NSCLC?
Recent Videos
